Brind.
  1. I-Mab presented clinical data for Givastomig, combining it with nivolumab and mFOLFOX6, while Trump-era tariffs benefited AI stocks.
  2. AI stocks are benefiting from Trump tariffs and onshoring, alongside potential merger talks involving Northern Trust and Bank of New York Mellon.

Merger talks between The Bank of New York Mellon and Northern Trust were prompted by the firms to assert independence, while both offer asset servicing and money management services.

3 reports, 0 independent Updated Jun 24
Gone quiet
Reports
3
Developments
1
Repetition
67%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

SpeculativeNo independent reporting found

Merger talks between The Bank of New York Mellon and Northern Trust were prompted by the firms to assert independence, while both offer asset servicing and money management services.

Who's involved

What this event is mainly about
The Bank of New York MellonNorthern Trust

Keep exploring

Part of

AI stocks are benefiting from Trump tariffs and onshoring, alongside potential merger talks involving Northern Trust and Bank of New York Mellon. All 1 developments

Within I-Mab presented clinical data for Givastomig, combining it with nivolumab and mFOLFOX6, while Trump-era tariffs benefited AI stocks.

The entities involved

Related events

Coverage

Newest first; wire copies grouped
  • Unknown outlet
  • Unknown outlet
  • Unknown outlet